Deviating from a guidance [Design Issues]

posted by Pharma_88 – India, 2024-05-21 10:32 (29 d 03:16 ago) – Posting: # 24005
Views: 1,123

Dear Helmut,

Thank you. Yes for For submission study, will definitely initiate CC with FDA. Since this is a pilot study where main objective is to assess the possibility of the single dose administration effect on pharmacokinetic as well as safety. So any possibility to conduct parallel design study? if yes, how it will be designed?


Complete thread:

UA Flag
 Admin contact
23,058 posts in 4,840 threads, 1,641 registered users;
126 visitors (0 registered, 126 guests [including 10 identified bots]).
Forum time: 13:48 CEST (Europe/Vienna)

Even though it’s applied science we’re
dealin’ with, it still is – science!    Leslie Z. Benet

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz